Abstract
Abstract
Pegylated granulocyte colony-stimulating factor (peg-G-CSF) is a safe long-acting form of G-CSF to improve chemotherapy-induced neutropenia. However, hyper response of neutropenia can be induced soon after an administration of peg-G-CSF. Neutrophil response is sometimes associated to fever, bone pain, and headache, however, this drug is generally safe and well-tolerated in cancer patients. Acute renal failure is rare adverse event of peg-G-CSF. We observed severe cell lysis resulted in acute renal failure in a combination use of peg-G-CSF and dexamethasone.
Publisher
Research Square Platform LLC
Reference4 articles.
1. Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial;Gluz O;Ann Oncol. 2023 Apr
2. Ohsaka A, Kikuta A, Ohto H, Ohara A, Ishida A, Osada K, Tasaki T, Kamitamari A, Iwai A, Kai S, Maekawa T, Hoshi Y; Japan Society of Transfusion Medicine and Cell Therapy, Granulocyte Transfusion Task Force. Guidelines for safety management of granulocyte transfusion in Japan. Int J Hematol. 2010;91(2):201-8. doi: 10.1007/s12185-010-0506-z. Epub 2010 Feb 11. PMID: 20146029.
3. Liles WC, Rodger E, Dale DC. Combined administration of G-CSF and dexamethasone for the mobilization of granulocytes in normal donors: optimization of dosing. Transfusion. 2000;40(6):642-4. doi: 10.1046/j.1537-2995.2000.40060642.x. PMID: 10864982.
4. Authorship: OI, SY, and MU managed the patient’s case, contributed to the literature search, and wrote the manuscript. MU made substantial contributions to the concept and design of this report. MU was involved in the supervision of the manuscript. MU managed the research. All authors approved the final version of the manuscript.